Welcome to our dedicated page for Greater Cannabis SEC filings (Ticker: GCAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Greater Cannabis Company, Inc. (GCAN) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a publicly traded clinical stage biopharmaceutical company focused on cannabinoid therapeutics, GCANRx uses filings such as Form 8-K to report material corporate events that affect its capital structure, governance and strategic direction.
Among the notable items in GCAN’s recent filings are reverse stock split details and preferred stock designations. In a Form 8-K, the company reported implementing a 1-for-1,500 reverse stock split of its common stock, explaining how pre-split shares were combined into post-split shares, how fractional shares would be handled, and how the action affects shares issuable upon conversion of outstanding convertible debt, warrants and stock options. An amended 8-K clarified the effective and trading dates after an administrative oversight related to the FINRA Daily List.
Another 8-K describes the creation of Series B Convertible Preferred Stock through Articles of Amendment filed in Florida. The filing outlines the rights and limitations of this class, including its allocation of 51.0% of the total voting power when voting with common and Series A preferred shares, the absence of dividend rights, a stated liquidation preference and a defined conversion rate into common stock, along with adjustment mechanisms for stock splits, combinations and reorganizations.
Through this page, users can review GCANRx’s 8-K and related exhibits to understand how the company structures voting control, manages its share count and responds to corporate events. Stock Titan’s tools surface these filings as they are made available from EDGAR and apply AI-powered summaries to highlight key points in complex documents, such as the implications of a reverse split or the governance impact of a new preferred stock class.
Investors and researchers can use this filings archive to track GCAN’s material disclosures over time, including future annual reports on Form 10-K, quarterly reports on Form 10-Q and insider transaction reports on Form 4 as they become available.
The Greater Cannabis Company (GCAN) filed its Q3 2025 report. The company generated $0 revenue and reported a net loss of $36,099 for the quarter. For the nine months ended September 30, 2025, net loss was $669,369.
As of September 30, 2025, cash was $21,355 against $1,129,697 in current liabilities, resulting in a stockholders’ deficit of $(1,108,342). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The company completed a 1-for-1,500 reverse stock split in October 2025; shares outstanding were 900,256 as of September 30, 2025, and 944,935 as of October 22, 2025. During 2025, the FirstFire note accrued $306,323 in default penalties and interest; an amendment provides the note is deemed satisfied upon completion of the reverse split. On October 22, 2025, GCAN created Series B Convertible Preferred (1,000 shares), issuing it to the CEO in exchange for $20,000 of waived compensation; these shares carry 51.0% voting power.
The Greater Cannabis Company (GCAN) created a new Series B Convertible Preferred Stock and issued it to CEO Aitan Zacharin in exchange for waiving
Each Series B share is convertible at the holder’s option into common stock at a rate of 100,000 common shares per preferred share, subject to customary adjustments for stock splits or combinations. The super‑voting rights terminate if any Series B is converted in part or transferred to a third party, after which the shares vote on an as‑converted basis with other classes. The Series B has no dividend rights and a liquidation preference of $0.001 per share.
The Greater Cannabis Company (GCAN) amended its report to update timing for a reverse stock split. A 1-for-1,500 reverse split is effective as of the close of business on October 16, 2025, after a one-day delay due to a FINRA Daily List omission.
The stock will trade on a post-split basis starting October 17, 2025, under ticker GCAND for twenty trading days, with new CUSIP 391657202. Issued and outstanding common shares will be reduced from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Authorized shares and the $0.001 par value are unchanged. The split also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options.
The Greater Cannabis Company (GCAN) is implementing a 1-for-1,500 reverse stock split of its common stock, effective as of the close of business on October 15, 2025. The stock will begin trading on a post-split basis on October 16, 2025 under the temporary ticker GCAND for twenty trading days, with a new CUSIP 391657202.
The reverse split reduces issued and outstanding common shares from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders entitled to a fraction will receive one whole share. The action also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options. Authorized shares and par value ($0.001) remain unchanged, and the company notes it will have additional shares available for potential future issuance, without specific plans beyond honoring existing convertible and equity awards.